Loading
A public investment fund would match private money in the riskiest early trials of truly new cancer drugs, taking a small share of future royalties so that taxpayers gain when the bets pay off.
A sovereign or supranational fund co-invests one-to-one alongside private investors in phase 1 trials of assets that meet a first-in-class test (a target or mechanism with no approved analogue), in exchange for a royalty stake or equity. The fund's return is portfolio-level and long-term; its purpose is to lower the private cost of capital for novel mechanisms relative to me-too assets. The Cancer Prevention and Research Institute of Texas (CPRIT) and the California Institute for Regenerative Medicine (CIRM) show public bodies can invest in translational biotech with revenue-sharing and attract companies; the EU's Innovative Health Initiative and BARDA venture arms are related models.
Shares A diversified royalty pool that finances academic phase 1 trials across fifty assets, A fast IND-enabling fund that pays for toxicology and manufacturing in eight weeks, The valley of death between lab and product.
Shares A fast IND-enabling fund that pays for toxicology and manufacturing in eight weeks, The valley of death between lab and product.
Shares Government reinsurance for phase 2 failures of first-in-class cancer drugs, Incentives reward me-too drugs and marginal gains.
Shares A fast IND-enabling fund that pays for toxicology and manufacturing in eight weeks, The valley of death between lab and product.
Shares A fast IND-enabling fund that pays for toxicology and manufacturing in eight weeks, The valley of death between lab and product.
Shares A diversified royalty pool that finances academic phase 1 trials across fifty assets, The valley of death between lab and product.
Shares Government reinsurance for phase 2 failures of first-in-class cancer drugs, Incentives reward me-too drugs and marginal gains.
Shares A fast IND-enabling fund that pays for toxicology and manufacturing in eight weeks, The valley of death between lab and product.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/